A novel AXL kinase inhibitor from Norwegian biotech BerGenBio (OSE: BGBIO) is to be fast-tracked through a new Phase II trial program led by the British government.
The initiative is designed to provide an early indication of the potential for medicines to help the most vulnerable people with COVID-19.
BerGenBio has been trying to develop the candidate, bemcentinib, as a first-in-class cancer drug. It has also shown antiviral activity against several “enveloped” viruses, a category which includes the novel coronavirus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze